Affiliations: [a] Department of Pediatrics, Stony Brook Children’s Hospital, Stony Brook, NY, USA
| [b] Department of Preventive Medicine, Division of Community and Behavioral Health, Stony Brook Children’s Hospital, Stony Brook, NY, USA
| [c] Department of Pediatrics, Division of Neonatal-Perinatal Medicine, Stony Brook Children’s Hospital, Stony Brook, NY, USA
Correspondence:
[*]
Address for correspondence: Pooja Rathi, Stony Brook Children’s Hospital, Department of Pediatrics, HSC T11, Rm. 040, Stony Brook, NY 11794, USA. Tel.: +1 631 444 2020; Mobile: +1 408 406 2643; Fax: +1 631 444 8968; E-mail: pooja9rathi@gmail.com.
Abstract: BACKGROUND:Few studies exist that have evaluated the effects of indomethacin dosing frequency as a factor associated with successful patent ductus arteriosus closure in very low birth weight neonates. The objective of this study is to determine if indomethacin dosing strategy is associated with efficacy for initial patent ductus arteriosus management in very low birth weight neonates. METHODS:This retrospective review compared every 12 hour and every 24 hour indomethacin regimens primarily for efficacy in initial patent ductus arteriosus management, defined as an absence of repeat medical and/or surgical treatment, and secondarily for safety in both univariate and multivariate models. RESULTS:One hundred three very low birth weight neonates were included: 56 (54%) received every 12 hour and 47 (46%) underwent every 24 hour indomethacin dosing. Repeat medical and/or surgical patent ductus arteriosus treatment rates were similar between groups. Less ligation of the patent ductus arteriosus occurred with every 12 hour versus every 24 hour dosing (11% vs. 26%, p = 0.05), though this effect was mitigated controlling for birth weight and gestational age. Renal function, respiratory outcomes, feeding outcomes, length of stay, and mortality were similar between groups. CONCLUSIONS:Neither the every 12 hour nor the every 24 hour indomethacin regimen demonstrated inferior efficacy or safety for initial management of patent ductus arteriosus. Further prospective analysis of indomethacin dosing strategy is warranted.
